RxDoctor Payments Data

Peter Alford, MD

Pulmonary Disease · Hickory, NCNPI 1356333827

Payments from drug & device makers

$9,350in general payments, 2019–2025

Across 443 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$2K
  • AstraZeneca$1K
  • GSK$1K
  • Boehringer Ingelheim$963
  • Philips North America LLC$289
  • Genentech USA, Inc.$278
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$9,16698%
  • Education$1832%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,350 in reported general payments places this provider in the 70th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$15,869
Medicare patients
66
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$364,856
Prolastin CAlpha-1-Proteinase Inhibitor17$215,677
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$69,488
Pirfenidone19$42,815
Breztri AerosphereBudesonide/Glycopyr/Formoterol48$31,874
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$12,053
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$10,284
Breo ElliptaFluticasone/Vilanterol12$7,159
SymbicortBudesonide/Formoterol Fumarate11$2,305
Albuterol Sulfate HfaAlbuterol Sulfate83$2,201
Pramipexole DihydrochloridePramipexole Di-Hcl112$815
Modafinil18$303
Omeprazole34$186
Trazodone Hcl40$174
Montelukast Sodium21$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat$963$376,90945 claims
Grifols USA, LLCProlastin C$242$215,67717 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,390$86,931136 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,457$34,17959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →